ARTICLE | Company News
InSite, Nitten Pharmaceutical Co. Ltd. sales and marketing update
April 13, 2009 7:00 AM UTC
Nitten received exclusive rights to commercialize InSite's AzaSite azithromycin to treat ocular bacterial infections in Japan and Taiwan. Nitten will be responsible for obtaining regulatory approval....